Show simple item record

dc.contributor.authorAlbrecht, Joerg
dc.contributor.authorMaloney, Mary E.
dc.contributor.authorBrod, Bruce Alan
dc.date2022-08-11T08:08:21.000
dc.date.accessioned2022-08-23T15:52:09Z
dc.date.available2022-08-23T15:52:09Z
dc.date.issued2016-09-01
dc.date.submitted2017-06-02
dc.identifier.citationJ Am Acad Dermatol. 2016 Sep;75(3):603-5. doi: 10.1016/j.jaad.2016.03.053. Epub 2016 Jul 13. <a href="https://doi.org/10.1016/j.jaad.2016.03.053">Link to article on publisher's site</a>
dc.identifier.issn0190-9622 (Linking)
dc.identifier.doi10.1016/j.jaad.2016.03.053
dc.identifier.pmid27423978
dc.identifier.urihttp://hdl.handle.net/20.500.14038/29074
dc.description<p>Full author list omitted for brevity. For full list of authors see article.</p>
dc.description.abstractIn 2014, Medicare expenditures increased 12%, the largest increase reported since 2002, resulting in major concerns by both patients and physicians. Although costs are rising for both specialty drugs and generic medications,out-of-pocket costs, restrictive formularies,and health plan bureaucracies are limiting patients' access to necessary medications. In response, the Regulatory Policy Committee of the American Academy of Dermatology (AAD)/Association (AAD/A) convened a Task Force on Drug Pricing and Transparency. This editorial summarizes the issues addressed by the task force along with relevant AAD/A policy.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=27423978&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttps://doi.org/10.1016/j.jaad.2016.03.053
dc.subjectcoinsurances
dc.subjectdrug pricing
dc.subjectformulary tiering
dc.subjectgeneric drugs
dc.subjectout-of-pocket costs
dc.subjectpharmacy benefit managers
dc.subjectprior authorizations
dc.subjectDermatology
dc.subjectPharmacoeconomics and Pharmaceutical Economics
dc.titleThe state and consequences of dermatology drug prices in the United States
dc.typeEditorial
dc.source.journaltitleJournal of the American Academy of Dermatology
dc.source.volume75
dc.source.issue3
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/faculty_pubs/1301
dc.identifier.contextkey10243090
html.description.abstract<p>In 2014, Medicare expenditures increased 12%, the largest increase reported since 2002, resulting in major concerns by both patients and physicians. Although costs are rising for both specialty drugs and generic medications,out-of-pocket costs, restrictive formularies,and health plan bureaucracies are limiting patients' access to necessary medications. In response, the Regulatory Policy Committee of the American Academy of Dermatology (AAD)/Association (AAD/A) convened a Task Force on Drug Pricing and Transparency. This editorial summarizes the issues addressed by the task force along with relevant AAD/A policy.</p>
dc.identifier.submissionpathfaculty_pubs/1301
dc.contributor.departmentDivision of Dermatology, Department of Medicine
dc.source.pages603-5


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record